A Phase I Study of R04929097 in Combination With Gemcitabine in Patients With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Recommended phase II dose of RO4929097 in combination with gemcitabine hydrochloride, defined as the dose level in which no more than 1 of 6 patients or 0/3 experience DLT, graded according to NCI CTCAE version 4.0
研究概览
简要总结
This phase I trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 when given together with gemcitabine hydrochloride in treating patients with advanced solid tumors. Gamma-secretase inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gamma-secretase inhibitor RO4929097 together with gemcitabine hydrochloride may kill more tumor cells.
详细描述
PRIMARY OBJECTIVES:
I. To determine the safety profile and establish the maximum-tolerated dose and recommended phase II dose of gamma-secretase inhibitor RO4929097 in combination with gemcitabine hydrochloride in patients with advanced solid tumors.
SECONDARY OBJECTIVES:
I. To determine the pharmacokinetic profile of gamma-secretase inhibitor RO4929097 when given in combination with gemcitabine hydrochloride and to correlate the pharmacokinetic profile with toxicity and biological activity.
II. To assess the antitumor activity of gamma-secretase inhibitor RO4929097 and gemcitabine hydrochloride in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meets one of the following sets of criteria:
- •Histologically and/or cytologically confirmed solid malignancy
- •Metastatic or unresectable disease
- •Disease for which standard curative or palliative measures do not exist or are no longer effective
- •Histologically and/or cytologically confirmed adenocarcinoma of the pancreas (for patients in the expansion cohort)
- •Locally advanced or metastatic disease
- •No prior chemotherapy for advanced disease
- •Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
- •No known brain metastases
- •ECOG performance status (PS) 0-1 (Karnofsky PS 60-100%)
- •Life expectancy > 12 weeks
- •Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)
- •Leukocytes ≥ 3,000/mm^3
- •ANC ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Total bilirubin ≤ 1.25 times upper limit of normal (ULN)
- •AST/ALT ≤ 1.5 times ULN
- •Serum creatinine =< ULN OR creatinine clearance ≥ 60 mL/min
- •No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia, defined as less than the lower limit of normal despite adequate electrolyte supplementation
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use two forms of adequate contraception (i.e., barrier contraception and one other method of contraception) for ≥ 4 weeks before, during, and for ≥ 12 months after completion of study treatment
- •Able to swallow medication
- •No malabsorption syndrome or other condition that would interfere with intestinal absorption
- •No uncontrolled concurrent illness including, but not limited to, any of the following:
- •Ongoing or active infection
- •Symptomatic congestive heart failure
- •Unstable angina pectoris
- •Cardiac arrhythmia other than chronic, stable atrial fibrillation
- •Psychiatric illness or social situations that would limit compliance with study requirements
- •No baseline QTc > 450 msec (for male patients) or > 470 msec (for female patients)
- •No history of risk factors for QT interval prolongation including, but not limited to, a family or personal history of any of the following:
- •Long QT syndrome
- •Recurrent syncope without known etiology
- •Sudden unexpected death
- •No history of torsade de pointes or other significant cardiac arrhythmias or the need for concomitant meds with known potential to prolong QT interval or antiarrhythmics
- •No diarrhea ≥ grade 2 not under control with standard anti-diarrhea medications
- •No serologic positivity for hepatitis A, B, or C
- •No history of liver disease or other forms of hepatitis or cirrhosis
- •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or to gemcitabine hydrochloride
- •Female patients may not donate ova during or after completion of study treatment
- •Male patients may not donate sperm during and for ≥ 12 months after completion of study treatment
- •Patients may not donate blood during and for ≥ 12 months after completion of study treatment
- •No other concurrent investigational or commercial agents or therapies administered with the intent to treat the patient's malignancy
- •Any number of prior therapies allowed
- •No prior therapy with a Notch inhibitor
- •At least 4 weeks since prior radiotherapy, chemotherapy, or systemic therapy (6 weeks if the last regimen included nitrosourea or mitomycin C) and recovered
- •Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for symptomatic palliation
- •Patients in the expansion cohort must meet the following criteria:
- •No prior chemotherapy for advanced disease except for fluorouracil (with or without folinic acid) or gemcitabine hydrochloride given concurrently with radiotherapy as a "radiosensitizer"
- 另有 10 项未显示
排除标准
- 未提供
研究组 & 干预措施
Treatment (RO4929097 and gemcitabine hydrochloride)
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: gamma-secretase/Notch signalling pathway inhibitor RO4929097 (Drug)
Treatment (RO4929097 and gemcitabine hydrochloride)
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: gemcitabine hydrochloride (Drug)
Treatment (RO4929097 and gemcitabine hydrochloride)
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: pharmacological study (Other)
Treatment (RO4929097 and gemcitabine hydrochloride)
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Recommended phase II dose of RO4929097 in combination with gemcitabine hydrochloride, defined as the dose level in which no more than 1 of 6 patients or 0/3 experience DLT, graded according to NCI CTCAE version 4.0
时间窗: 28 days
次要结局
- Objective response according to RECIST criteria 1.1(Up to 1 year)
- Cmax, Tmax, t 1/2, AUC0-24, and clearance of gamma-secretase/Notch signalling pathway inhibitor RO4929097 and gemcitabine hydrochloride when given together(Before dosing and at 1, 2, 4, 6, 8, and 24 hours after dosing on days 1 and 10; before dosing on days 3, 9, and 15; before dosing and 1 and 2 hours after dosing on day 8; and any time on day 22 of course 1 and before drug dosing on day 1 of course 2)